BioCentury
ARTICLE | Company News

Management tracks

October 15, 2015 12:59 AM UTC

Cell programming company Fate Therapeutics Inc. (NASDAQ:FATE) said Scott Wolchko will succeed Christian Weyer as president and CEO following Weyer's resignation on Nov. 30. Wolchko was Fate's CFO. Fate also named Daniel Shoemaker CSO and promoted Stewart Abbot to chief development officer. Shoemaker was Fate's chief technology officer and Abbot was VP of translational research.

Cancer play Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) said CMO Adam Craig will step down at YE15 to pursue other opportunities. The company is searching for a replacement. ...